Announcements

We invite you to explore the following top five papers published in 2024 in the “Radiopharmaceutical Sciences” Section:

1. “Alpha-Emitting Radionuclides: Current Status and Future Perspectives”
by Matthias Miederer, Martina Benešová-Schäfer, Constantin Mamat, David Kästner, Marc Pretze, Enrico Michler, Claudia Brogsitter, Jörg Kotzerke, Klaus Kopka, David A. Scheinberg et al.
Pharmaceuticals 2024, 17(1), 76; https://doi.org/10.3390/ph17010076
Available online: https://www.mdpi.com/1424-8247/17/1/76

2. “Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands”
by Kim E. de Roode, Lieke Joosten and Martin Behe
Pharmaceuticals 2024, 17(2), 256; https://doi.org/10.3390/ph17020256
Available online: https://www.mdpi.com/1424-8247/17/2/256

3. “Integrating Artificial Intelligence and PET Imaging for Drug Discovery: A Paradigm Shift in Immunotherapy”
by Jeremy P. McGale, Harrison J. Howell, Arnaud Beddok, Mickael Tordjman, Roger Sun, Delphine Chen, Anna M. Wu, Tarek Assi, Samy Ammari and Laurent Dercle
Pharmaceuticals 2024, 17(2), 210; https://doi.org/10.3390/ph17020210
Available online: https://www.mdpi.com/1424-8247/17/2/210

4. “Functionalization of ⁶⁸Ga-Radiolabeled Nanodiamonds with Octreotide Does Not Improve Tumor-Targeting Capabilities”
by Thomas Wanek, Marco Raabe, Md Noor A Alam, Thomas Filip, Johann Stanek, Mathilde Loebsch, Christian Laube, Severin Mairinger, Tanja Weil and Claudia Kuntner
Pharmaceuticals 2024, 17(4), 514; https://doi.org/10.3390/ph17040514
Available online: https://www.mdpi.com/1424-8247/17/4/514

5. “Preparation of a Zirconium-89 Labeled Clickable DOTA Complex and Its Antibody Conjugate”
by Falguni Basuli, Olga Vasalatiy, Jianfeng Shi, Kelly C. Lane, Freddy E. Escorcia and Rolf E. Swenson
Pharmaceuticals 2024, 17(4), 480; https://doi.org/10.3390/ph17040480
Available online: https://www.mdpi.com/1424-8247/17/4/480

We invite you to explore the following top five papers published in 2024 in the “Pharmaceutical Technology” Section:

1. “Nanoparticle-Mediated Drug Delivery Systems for Precision Targeting in Oncology”
by Kamelia Hristova-Panusheva, Charilaos Xenodochidis, Milena Georgieva and Natalia Krasteva
Pharmaceuticals 2024, 17(6), 677; https://doi.org/10.3390/ph17060677
Available online: https://www.mdpi.com/1424-8247/17/6/677

2. “Current Strategies and Therapeutic Applications of Mesenchymal Stem Cell-Based Drug Delivery”
by Yasunari Matsuzaka and Ryu Yashiro
Pharmaceuticals 2024, 17(6), 707; https://doi.org/10.3390/ph17060707
Available online: https://www.mdpi.com/1424-8247/17/6/707

3. “Magnetic Hyperthermia Therapy for High-Grade Glioma: A State-of-the-Art Review”
by Benjamin Rodriguez, Daniel Rivera, Jack Y. Zhang, Cole Brown, Tirone Young, Tyree Williams, Sakibul Huq, Milena Mattioli, Alexandros Bouras and Constantinos G. Hadjpanayis
Pharmaceuticals 2024, 17(3), 300; https://doi.org/10.3390/ph17030300
Available online: https://www.mdpi.com/1424-8247/17/3/300

4. “A Novel Combined Dry Powder Inhaler Comprising Nanosized Ketoprofen-Embedded Mannitol-Coated Microparticles for Pulmonary Inflammations: Development, In Vitro–In Silico Characterization, and Cell Line Evaluation”
by Heba Banat, Ildikó Csóka, Dóra Paróczai, Katalin Burian, Árpád Farkas and Rita Ambrus
Pharmaceuticals 2024, 17(1), 75; https://doi.org/10.3390/ph17010075
Available online: https://www.mdpi.com/1424-8247/17/1/75

5. “Topical Delivery of Tofacitinib in Dermatology: The Promise of a Novel Therapeutic Class Using Biodegradable Dendritic Polyglycerol Sulfates”
by Fatemeh Zabihi, Mariam Cherri, Xiao Guo, Fiorenza Rancan, Fabian Schumacher, Ehsan Mohammadifar, Burkhard Kleuser, Wolfgang Bäumer, Michael Schirner, Annika Vogt et al.
Pharmaceuticals 2024, 17(1), 77; https://doi.org/10.3390/ph17010077
Available online: https://www.mdpi.com/1424-8247/17/1/77

We invite you to explore the following top five papers published in 2024 in the “Biopharmaceuticals” Section:

1. “Microbial Biosurfactants: Antimicrobial Activity and Potential Biomedical and Therapeutic Exploits”
by Patricia Puyol McKenna, Patrick J. Naughton, James S. G. Dooley, Nigel G. Ternan, Patrick Lemoine and Ibrahim M. Banat
Pharmaceuticals 2024, 17(1), 138; https://doi.org/10.3390/ph17010138
Available online: https://www.mdpi.com/1424-8247/17/1/138

2. “A Comprehensive Review of Silver and Gold Nanoparticles as Effective Antibacterial Agents”
by Ricardo Aguilar-Garay, Luis F. Lara-Ortiz, Maximiliano Campos-López, Dafne E. Gonzalez-Rodriguez, Margoth M. Gamboa-Lugo, Jorge A. Mendoza-Pérez, Álvaro Anzueto-Ríos and Dulce E. Nicolás-Álvarez
Pharmaceuticals 2024, 17(9), 1134; https://doi.org/10.3390/ph17091134
Available online: https://www.mdpi.com/1424-8247/17/9/1134

3. “Insights into Immune Exhaustion in Chronic Hepatitis B: A Review of Checkpoint Receptor Expression”
by João Panão Costa, Armando de Carvalho, Artur Paiva and Olga Borges
Pharmaceuticals 2024, 17(7), 964; https://doi.org/10.3390/ph17070964
Available online: https://www.mdpi.com/1424-8247/17/7/964

4. “A Monocarbonyl Curcuminoid Derivative Inhibits the Activity of Human Glutathione Transferase A4-4 and Chemosensitizes Glioblastoma Cells to Temozolomide”
by Steliana Tsouri, Evanthia Tselo, Georgios E. Premetis, Veronika Furlan, Panagiota D. Pantiora, Barbara Mavroidi, Dimitris Matiadis, Maria Pelecanou, Anastassios C. Papageorgiou, Urban Bren et al.
Pharmaceuticals 2024, 17(3), 365; https://doi.org/10.3390/ph17030365
Available online: https://www.mdpi.com/1424-8247/17/3/365

5. “Potential of DPD ((S)-4,5-dihydroxy-2,3-pentanedione) Analogs in Microparticulate Formulation as Vaccine Adjuvants”
by Devyani Joshi, Sarthak Shah, Christiane Chbib and Mohammad N. Uddin
Pharmaceuticals 2024, 17(2), 184; https://doi.org/10.3390/ph17020184
Available online: https://www.mdpi.com/1424-8247/17/2/184

We invite you to explore the following top five papers published in 2024 in the “Medicinal Chemistry” Section.

1. “A Comprehensive Review on Deep Eutectic Solvents and Its Use to Extract Bioactive Compounds of Pharmaceutical Interest”
by Cátia Ferreira and Mafalda Sarraguça
Pharmaceuticals 2024, 17(1), 124; https://doi.org/10.3390/ph17010124
Available online: https://www.mdpi.com/1424-8247/17/1/124

2. “Recent Advances in Pyrimidine-Based Drugs”
by Baskar Nammalwar and Richard A. Bunce
Pharmaceuticals 2024, 17(1), 104; https://doi.org/10.3390/ph17010104
Available online: https://www.mdpi.com/1424-8247/17/1/104

3. “The Role of Small Molecules Containing Fluorine Atoms in Medicine and Imaging Applications”
by Emily Henary, Stefanie Casa, Tyler L. Dost, Joseph C. Sloop and Maged Henary
Pharmaceuticals 2024, 17(3), 281; https://doi.org/10.3390/ph17030281
Available online: https://www.mdpi.com/1424-8247/17/3/281

4. “Study of the Lipophilicity and ADMET Parameters of New Anticancer Diquinothiazines with Pharmacophore Substituents”
by Daria Klimoszek, Małgorzata Jeleń, Małgorzata Dołowy and Beata Morak-Młodawska
Pharmaceuticals 2024, 17(6), 725; https://doi.org/10.3390/ph17060725
Available online: https://www.mdpi.com/1424-8247/17/6/725

5. “De Novo Drug Design Using Transformer-Based Machine Translation and Reinforcement Learning of an Adaptive Monte Carlo Tree Search”
by Dony Ang, Cyril Rakovski and Hagop S. Atamian
Pharmaceuticals 2024, 17(2), 161; https://doi.org/10.3390/ph17020161
Available online: https://www.mdpi.com/1424-8247/17/2/161

1. “Use of Medicinal Plants in the Process of Wound Healing: A Literature Review”
by Mayra Cedillo-Cortezano, Luis Ruben Martinez-Cuevas, Jesús A. Márquez López, Ingrid L. Barrera López,  Samantha Escutia-Perez and Vera L. Petricevich
Pharmaceuticals 2024, 17(3), 303; https://doi.org/10.3390/ph17030303
Available online: https://www.mdpi.com/1424-8247/17/3/303

2. “Exploring Synergistic Interactions between Natural Compounds and Conventional Chemotherapeutic Drugs in Preclinical Models of Lung Cancer”
by Mihaela Boța, Lavinia Vlaia, Alex-Robert Jîjie, Iasmina Marcovici, Flavia Crişan, Cristian Oancea, Cristina Adriana Dehelean, Tudor Mateescu and Elena-Alina Moacă
Pharmaceuticals 2024, 17(5), 598; https://doi.org/10.3390/ph17050598  
Available online: https://www.mdpi.com/1424-8247/17/5/598

3. “Phytosterols and the Digestive System: A Review Study from Insights into Their Potential Health Benefits and Safety”
by  Edyta Miszczuk,  Andrzej Bajguz,  Łukasz Kiraga,  Kijan Crowley and Magdalena Chłopecka
Pharmaceuticals 2024, 17(5), 557; https://doi.org/10.3390/ph17050557
Available online: https://www.mdpi.com/1424-8247/17/5/557

4. “Biochanin A Inhibits the Growth and Biofilm of Candida Species“
by Monika Janeczko and Elżbieta Kochanowicz
Pharmaceuticals 2024, 17(1), 89; https://doi.org/10.3390/ph17010089
Available online: https://www.mdpi.com/1424-8247/17/1/89

5. “Anti-Atopic Effect of Scutellaria baicalensis and Raphanus sativus on Atopic Dermatitis-like Lesions in Mice by Experimental Verification and Compound-Target Prediction”
by  Jeongmin Lee,  Yun-Soo Seo,  A Yeong Lee,  Hyeon-Hwa Nam,  Kon-Young Ji,  Taesoo Kim,  Sanghyun Lee,  Jin Won Hyun,  Changjong Moon,  Yongho Cho et al.
Pharmaceuticals 2024, 17(3), 269; https://doi.org/10.3390/ph17030269
Available online: https://www.mdpi.com/1424-8247/17/3/269

Name: Dr. Wenyi Li
Affiliation: Department of Biochemistry and Chemistry, La Trobe Institute for Molecular

We wish to congratulate Dr. Wenyi Li on winning the Pharmaceuticals Young Investigator Award. We had the pleasure of inviting him for this interview, in which we learned more about his background, views, and interests.

The following is a brief interview with Dr. Wenyi Li:

1. Could you give a brief introduction of yourself to the readers? Could you introduce your current research direction and provide an update on your progress?
I am Dr Wenyi Li, a Senior Lecturer and NHMRC Investigator at La Trobe University, Australia. My research focuses on designing innovative antimicrobial peptides to combat antibiotic-resistant bacterial infections. My previous and current work aims to use chemical biology approaches to develop novel antimicrobial peptides and understand how these peptides can target essential bacterial processes, including membrane disruption.

2. Which research topics do you think will be of particular interest to the research community in the coming years?
Antimicrobial resistance and developing new antibiotics are critical research priorities. Given that antimicrobial peptides represent a promising alternative class with distinct mechanisms less prone to existing resistance, how to better translate the findings in antimicrobial peptides to clinical application remains a big challenge and is attracting a lot of interest in the research community.

3. Could you share any particularly interesting or unexpected results you have discovered so far in your research?
It is known that most antimicrobial peptides can target the bacterial membrane and lead to membrane disruption. However, some antimicrobial peptides can penetrate bacterial cells and target intracellular processes like nucleic acid and protein synthesis. Interestingly, chemically dimerizing such peptides changes their modes of action by targeting membrane disruption.

4. Do you have any advice for aspiring young researchers looking to make a meaningful impact in their respective fields?
One quote that I find particularly inspiring and would like to share with next-generation researchers comes from the renowned physicist Enrico Fermi: “There are two possible outcomes: if the result confirms the hypothesis, then you've made a measurement. If the result is contrary to the hypothesis, then you've made a discovery.” For me, this quote deeply highlights the value of both validation and unexpected findings in research, reminding me that progress is made not only through success but also through the unknown/failure.

5. As the winner of this award, would you like to take a moment to share your thoughts with our readers or express gratitude towards those who have played a significant role in your research accomplishments?
I am truly honored and grateful for this prestigious award. I would like to take the opportunity to thank my family for their kindest support, my mentors who nurtured my passion, and my colleagues, collaborators, and students whose hard work has been invaluable. This recognition motivates me to continue pursuing high-risk, high-impact peptide research that can benefit the community.

On behalf of the Editorial Office of Pharmaceuticals (ISSN: 1424-8247), we would like to thank you for your invaluable contributions as a reviewer for our journal. We are currently inviting distinguished scholars to join our Reviewer Board, and we would be delighted to receive your application, including a comprehensive academic CV, at pharmaceuticals@mdpi.com.

The requirements for applicants are as follows:

• Must hold a Ph.D. or be an M.D;
• Must have relevant research experience and published articles in the field of pharmaceutical science, a clear research direction, and familiarity with cutting-edge research in the field;
• Must have some experience in reviewing manuscripts and be able to complete reviewing work independently;
• Must have a scientific attitude to research and be able to evaluate manuscripts objectively, fairly, and on time.

The benefits of being a Reviewer Board Member include the following:

• After joining, the Editorial Office will issue an RBM certificate, and your personal information will appear on the official Pharmaceuticals homepage: https://www.mdpi.com/journal/pharmaceuticals/submission_reviewers;
• The Editorial Office will vote for an “Outstanding Reviewer” annually and issue honorary certificates and corresponding awards. Experts who carry out outstanding work have the opportunity to become members of the Editorial Board of Pharmaceuticals;
• Higher-value vouchers will be granted to thorough and timely reviewers. These vouchers can be used for all MDPI journals;
• Opportunities are given to participate in academic activities sponsored by Pharmaceuticals.

We appreciate your past contributions and look forward to the possibility of collaborating with you further.

World Malaria Day, observed annually on 25 April, is a global reminder of the urgent need to stay focused on the fight against malaria—a preventable and treatable disease that still threatens millions of lives, especially in vulnerable communities. Despite considerable progress over the past two decades, malaria continues to take a heavy toll, particularly in sub-Saharan Africa, where children under five remain at most risk.

The theme for 2025, “Malaria Ends with Us: Reinvest, Reimagine, Reignite”, is a powerful call to action. It is a strong reminder that the fight against malaria is not over, and that the power to end it lies with all of us.

In recognition of this vital cause, MDPI is spotlighting impactful research across a selection of its journals, highlighting contributions that advance the understanding, prevention, and treatment of malaria. Featured journals include Cells, Insects, Journal of Clinical Medicine (JCM), Metabolites, Parasitologia, Pathogens, Pharmaceuticals, Reports, and TropicalMed. By bringing these articles to the forefront, MDPI reaffirms its commitment to open access knowledge and global health equity.

Prof. Tu Youyou was awarded the Nobel Prize in Physiology or Medicine in 2015 for discovering artemisinin, a drug that has significantly reduced the mortality rates for patients suffering from malaria.

To honor Prof. Tu Youyou’s remarkable contributions and to continue with her achievements, MDPI established the Tu Youyou Award in 2016. This award aims to acknowledge exceptional scholars committed to the research fields of natural products chemistry and medicinal chemistry.

The winners of the 2024 Tu Youyou Award will be announced on 30 April. Visit the award website for the latest updates!

“Blood Source and Anesthetics Effects on the Maintenance of Anopheles darlingi in the Lab-Rearing Condition”
by José Daniel Costa Pontual, Natália Vitória Coelho, Najara Akira Costa dos Santos, Alessandra da Silva Bastos, Jéssica Evangelista Araújo, Alice Oliveira Andrade, Jansen Fernandes Medeiros and Maisa da Silva Araujo
Insects 2025, 16(3), 281; https://doi.org/10.3390/insects16030281

“Identification of Bioactive Metabolites of Capirona macrophylla by Metabolomic Analysis, Molecular Docking, and In Vitro Antiparasitic Assays”
by Joseph Evaristo, Elise de Laia, Bruna Tavares, Esdras Mendonça, Larissa Grisostenes, Caroline Rodrigues, Welington do Nascimento, Carolina Garcia, Sheila Guterres, Fábio Nogueira et al.
Metabolites 2025, 15(3), 157; https://doi.org/10.3390/metabo15030157

“Duplication of a Type-P5B-ATPase in Laverania and Avian Malaria Parasites and Implications About the Evolution of Plasmodium”
by Mark F. Wiser
Parasitologia 2025, 5(1), 6; https://doi.org/10.3390/parasitologia5010006

“Effect of Health Education Intervention on Knowledge and Adherence to Intermittent Preventive Treatment of Malaria in Pregnancy Among Women”
by Pauline N. Atser, Gommaa Hayat and Uchenna B. Okafor
Healthcare 2025, 13(2), 105; https://doi.org/10.3390/healthcare13020105

“Uncovering the Mechanism of Action of Antiprotozoal Agents: A Survey on Photoaffinity Labeling Strategy”
by Alessandro Giraudo, Cristiano Bolchi, Marco Pallavicini, Roberto Di Santo, Roberta Costi and Francesco Saccoliti
Pharmaceuticals 2025, 18(1), 28; https://doi.org/10.3390/ph18010028

“Contribution of Magnetic Resonance Imaging Studies to the Understanding of Cerebral Malaria Pathogenesis”
by Alicia Comino Garcia-Munoz, Isabelle Varlet, Georges Emile Grau, Teodora-Adriana Perles-Barbacaru and Angèle Viola
Pathogens 2024, 13(12), 1042; https://doi.org/10.3390/pathogens13121042

“Prophylaxis Failure and Successful Management of Delayed-Onset Malaria with Renal Complications: A Case Report with Oral Artemether-Lumefantrine Treatment”
by Ilir Tolaj, Gramoz Bunjaku, Murat Mehmeti and Yllka Begolli
Reports 2023, 6(4), 53; https://doi.org/10.3390/reports6040053

“Sensitivity Assessment of a Multiplex and Real-Time PCR Protocols for the Detection of Malaria in External Quality Control Samples in the Malaria Reference Center in Greece”
by Nikolaos Tegos, Christos Goumenopoulos, Anastasia Mpimpa, Vasilios Papavasilopoulos, Stavroula Beleri and Eleni Patsoula
Parasitologia 2024, 4(2), 150-161; https://doi.org/10.3390/parasitologia4020013

“Prevention of Malaria in Pregnant Women and Its Effects on Maternal and Child Health, the Case of Centre Hospitalier de Kingasani II in the Democratic Republic of the Congo”
by Japhet Kabalu Tshiongo, Trésor Zola Matuvanga, Patrick Mitashi, Vivi Maketa, Henk D. F. H. Schallig, Petra F. Mens, Hypolite Muhindo Mavoko and Junior Matangila Rika
Trop. Med. Infect. Dis. 2024, 9(5), 92; https://doi.org/10.3390/tropicalmed9050092

“An Epidemiological Survey of Malaria Infection in Espírito Santo State, Brazil, from 2007 to 2017”
by Nayna Carvalho Oliveira, Lais Rosa Boscalha, Cinthia Emerich Toledo, Felipe Sarlo Pezzin, Bruno Costanza Cisari, Suellen Rodrigues Maran, Laís Rodrigues Diniz, Pedro Henrique Schultz Corcino Freitas, Adenilton Cruzeiro, Frederico Eutropio et al.
Parasitologia 2023, 3(3), 215-222; https://doi.org/10.3390/parasitologia3030022

“Low Prevalence of Plasmodium falciparum Histidine-Rich Protein 2 and 3 Gene Deletions—A Multiregional Study in Central and West Africa”
by Tina Krueger, Moses Ikegbunam, Abel Lissom, Thaisa Lucas Sandri, Jacques Dollon Mbama Ntabi, Jean Claude Djontu, Marcel Tapsou Baina, Roméo Aimé Laclong Lontchi, Moustapha Maloum, Givina Zang Ella et al.
Pathogens 2023, 12(3), 455; https://doi.org/10.3390/pathogens12030455

“Impact of the COVID-19 Pandemic on Malaria Control in Africa: A Preliminary Analysis”
by Liping Gao, Qi Shi, Zhiguo Liu, Zhenjun Li and Xiaoping Dong
Trop. Med. Infect. Dis. 2023, 8(1), 67; https://doi.org/10.3390/tropicalmed8010067

1. “Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective”
by David Danielpour
Pharmaceuticals 2024, 17(4), 533; https://doi.org/10.3390/ph17040533
Available online: https://www.mdpi.com/1424-8247/17/4/533

2. “Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database”
by Rosanna Ruggiero, Annamaria Mascolo, Angela Spezzaferri, Claudia Carpentieri, Daniele Torella, Liberata Sportiello, Francesco Rossi, Giuseppe Paolisso and Annalisa Capuano
Pharmaceuticals 2024, 17(2), 147; https://doi.org/10.3390/ph17020147
Available online: https://www.mdpi.com/1424-8247/17/2/147

3. “Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows”
by Maria Chianese, Gianluca Screm, Francesco Salton, Paola Confalonieri, Liliana Trotta, Mariangela Barbieri, Luca Ruggero, Marco Mari, Nicolò Reccardini, Pietro Geri et al.
Pharmaceuticals 2024, 17(6), 709; https://doi.org/10.3390/ph17060709
Available online: https://www.mdpi.com/1424-8247/17/6/709

4. “View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences”
by Guglielmina Froldi
Pharmaceuticals 2024, 17(4), 478; https://doi.org/10.3390/ph17040478
Available online: https://www.mdpi.com/1424-8247/17/4/478

5. “A Review of Current and Pipeline Drugs for Treatment of Melanoma”
by Nicole Natarelli, Sarah J. Aleman, Isabella M. Mark, Jasmine T. Tran, Sean Kwak, Elizabeth Botto, Shaliz Aflatooni, Michael J. Diaz and Shari R. Lipner
Pharmaceuticals 2024, 17(2), 214; https://doi.org/10.3390/ph17020214
Available online: https://www.mdpi.com/1424-8247/17/2/214

We cordially invite you to attend The 1st International Electronic Conference on Medicinal Chemistry and Pharmaceutics (ECMC-P 2025). This conference is organized by the MDPI journals Pharmaceuticals (ISSN: 1424-8247; Impact Factor: 4.3) and Pharmaceutics (ISSN: 1999-4923; Impact Factor: 4.9), and it will take place virtually from 1 to 30 November 2025.

Conference Chairs:

• Prof. Dr. Maria Emília Sousa, Laboratory of Organic and Pharmaceutical Chemistry, Faculty of Pharmacy, University of Porto, Porto, Portugal;
• Prof. Dr. Patrick J. Sinko, Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA;
• Dr. Alfredo Berzal-Herranz, Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra, (IPBLN-CSIC), Spain.

Topics of Interest:

• Small molecules as drug candidates;
• Biomolecules, natural products, phages, and cells as therapeutic tools;
• Biological targets and biomarkers;
• Radiopharmaceutical sciences, radiochemistry, (hybrid) imaging, and nuclear medicine;
• Nanotechnology;
• Pharmacokinetics and pharmacodynamics;
• Pharmaceutical preparations and drug delivery.

Important Dates:

• Abstract Submission Deadline: 21 September 2025;
• Acceptance Notification Deadline: 5 October 2025;
• Registration Deadline: 31 October 2025.

Guide for Authors:

To submit your abstract, please click on the following link: https://sciforum.net/user/submission/create/1358.

To register for the event, please click on the following link: https://sciforum.net/event/ECMC-P2025?subscribe&section=#registration.

For details regarding abstract submission and poster and slide submission, please refer to the following link: https://sciforum.net/event/ECMC-P2025?section=#instructions.

Awards:
The open access, peer-reviewed journals Pharmaceuticals and Pharmaceutics will present awards totaling CHF 1600 for the Best Poster, Best Slideshow, Best Flash Communication, and Best Communication, as well as an award totaling CHF 500 for the Best Invited Lecture. Additionally, one participant will be granted the opportunity to engage in a One-Day Microwave Practice/Test.

For any inquiries regarding the event, please contact ecmc-p@mdpi.com.

We look forward to seeing you at the 1st International Electronic Conference on Medicinal Chemistry and Pharmaceutics.